Jessica Herrera-Flanigan

Delivering on our ambitious goals requires us to have a strong, multi-disciplinary board that has not only the expertise, but the passion, to help us reimagine everyday health. Kofi Amoo-Gottfried has both, and I’m so excited to be announcing his nomination for election to our board. With decades of experience as a storyteller and brand builder, he has served as the architect for global brands that have redefined everything from human connection to home delivery. news.hims.com/newsroom/hims-…

As of this morning, providers on our platform can now send prescriptions for Zepbound® vials and KwikPen®, as well as Foundayo™, to the LillyDirect® pharmacy and access self-pay pricing for our customers because of an expansion in our platform’s functionality. In many ways, today reminds me of Netflix’s early days, when everyone talked about whether they would have the latest blockbuster in their catalog. As if Netflix’s success depended on its ability to become the distribution channel for a single film. They were missing the forest for the trees: Netflix wasn’t just renting DVDs. It was changing consumer behavior by ruthlessly prioritizing choice and inventing new pathways to the things people wanted the most. By offering a full range of FDA-approved GLP-1s on our platform, we’re similarly giving our customers more choices through all the tools we have available – and we’ll continue to push here on behalf of everyone who depends on us for their care. Read more on how we’re making this possible, including important info, here: news.hims.com/newsroom/full-…

Women’s health shouldn’t be on backorder. The national estrogen patch shortage is a systemic failure, but at Hers, we refuse to let women be an afterthought. We’ve built a reliable supply to help ensure they can access the uninterrupted, personalized menopause care women deserve. More here from @JShepherd_MD, Chief Medical Officer of Hers: news.hims.com/newsroom/navig…

Today, the FDA moved towards bringing regulatory clarity on peptide therapy. At Hims & Hers, we believe innovation in longevity care must be guided by safety, transparency, and clinical excellence. Read our statement from Dr. Pat Carroll: news.hims.com/newsroom/appla…

Almost two weeks ago, we kicked off our strategic shift in our weight loss business and shipped our first @novonordisk medicines. We believe we’re on track to deliver more than 100K prescriptions for Wegovy products every month. More treatment options mean more customers can find what works best for them. Helping people get – and stay – healthy is why we’re here. Important Info: news.hims.com/disclaimers/di…

For years, progress in healthcare has lagged behind technological innovation – leading to fragmented, reactive systems that are stuck in the past. That’s about to change. Hear from CTO Mo Elshenawy about how we’ve built AI as the operating system for care, empowering customers to take control of their health by making concierge care more accessible than ever. More important info below: news.hims.com/newsroom/build…

Customer access should move at the same speed as innovation. When the healthcare industry works together to reach individuals, it does. Since last week, thousands of people have signed up for our Wegovy® waitlist. Starting today, eligible Hims & Hers customers can start their journeys with @novonordisk’s FDA-approved Wegovy® Pill & Wegovy® Pen and partner with their provider on a comprehensive weight loss program designed to help them achieve their goals. We take our role as the largest global consumer health platform seriously, and I can’t wait to keep finding ways to make sure everyone can access the tools they need to feel great. Read more below from Dr. Craig, our Head of Weight Loss, on what’s available today. (And if you’re starting your Wegovy journey with us today, tag me and tell me how it’s going!) More details, including important info, here: news.hims.com/newsroom/wegov…

A new era of weight management is coming to Hims & Hers. Soon: access to FDA-approved GLP-1 treatments — including Wegovy® pills and injections. Join our exclusive pre-launch waitlist today: bit.ly/4shiU6p 𝘞𝘦𝘨𝘰𝘷𝘺® 𝘪𝘴 𝘢 𝘳𝘦𝘨𝘪𝘴𝘵𝘦𝘳𝘦𝘥 𝘵𝘳𝘢𝘥𝘦𝘮𝘢𝘳𝘬 𝘰𝘧 𝘕𝘰𝘷𝘰 𝘕𝘰𝘳𝘥𝘪𝘴𝘬 𝘈/𝘚.

Wegovy. Coming soon! $hims hims.com/weight-loss/wa…

Transforming an industry requires helping people visualize a future unlike anything they've seen before. It means telling a story that changes what people believe is possible. Kathy Beiser, our new Chief Communications Officer, has decades of experience doing exactly that. She’s a 4-time CCO and PR agency vet who has spent her career launching, building, and elevating corporate brands at Discover, Kaiser Permanente, Edelman, Hilton Worldwide and most recently Eli Lilly and Company. But more than that, Kathy is our kind of people. She’s values-driven, consumer-obsessed, passionate, and a builder who isn't afraid of a challenge. She's been working with me and our executive leaders now for just a few weeks, but it feels like she's been part of our team for a decade. Couldn't be more thrilled to have her for this next phase as we strive to build the most beloved and trusted health brand globally. Welcome, Kathy! news.hims.com/newsroom/hims-…

Excited to introduce Hims & Hers Benefits - connecting subscribers with products that support whole body health. To kick off, we’re partnering with @Prenuvo @Eightsleep to offer whole body MRI scans and adaptive bed systems. And this is just the start! news.hims.com/newsroom/with-…

We’re making a strategic shift in our weight loss business to reflect what we believe is the future of the industry, starting with a strategic collaboration with @novonordisk. Later this month, Hims & Hers customers will have access to Novo Nordisk’s FDA-approved oral and injectable Wegovy® through our platform at self-pay prices. This evolution will make us the largest global consumer health platform providing access to affordable, approved medications. It’s just the start of what we think is possible when innovators work together to help more people feel great. More at the link below ⬇️ investors.hims.com/news/news-deta… Important info here: news.hims.com/disclaimers/di…

We founded Hims & Hers to help more people feel great. To disrupt a broken healthcare system and create a new model of health where innovators work together to deliver access to care that actually serves everyday people. We align how we operate with where we see major growth opportunities and in a way that allows us to meet our customers where they are (and where they want to go). That’s why, later this month, Hims & Hers customers will have access to FDA-approved medications from @novonordisk as a part of a strategic collaboration. The weight loss landscape is completely different today than it was when we first entered the category. FDA-approved GLP-1 treatments are now more accessible, with greater affordability and more flexible dosing options and form factors. These market changes are shifting consumer demand towards these branded medications. We’re moving our model forward another step with this strategic shift in our US weight loss business. This evolution will make us the largest global consumer health platform providing access to more affordable, approved medications. We will continue to innovate across our platform, keeping what’s best for consumers as our North Star. There's challenging, important work in front of us, and I've never been more excited about the path ahead. Just like we always do, Hims & Hers will rise to meet the moment. More here: investors.hims.com/news/news-deta… Important info here: news.hims.com/disclaimers/di…

We have nonstop flights to Japan if anyone wants to go hang out with their new close personal friend Punch.

OJO‼️Cuentas creadas por los propios grupos criminales buscan generar caos y pánico con reportes falsos. Son cuentas anónimas que operan como un aparato de propaganda. Piensen en los narco bloqueos, pero en línea. La desinformación también puede ser un arma de confusión masiva.

🌏We’re continuing our global expansion! Today, we’re announcing that we’ve agreed to acquire Eucalyptus, an international leader in consumer health. With this deal, we believe we’re on the path to becoming the leading global consumer health platform, where everyone can access the best care for their needs, regardless of where they live. Healthcare challenges are global, and solving them looks different for everyone. We can’t wait to work together to bring a local approach to a global problem. More at the link below ⬇️ investors.hims.com/news/news-deta…

Today, we’re on the fast track to becoming the leading global consumer health platform: we’ve agreed to acquire Eucalyptus, an international innovator in digital health. We’ve spent several years investing in our international footprint because we know that the status quo in healthcare across the world still doesn’t put the individual at the center. When I met @_Timdoyle many years ago, I knew immediately that we shared a similar perspective on how to change the status quo. Helping people feel great means tackling multiple conditions and recognizing that one size doesn’t fit all. It requires a diversified platform that can meet almost anyone where they are with care that is built for them. It’s what makes Tim and his team leaders outside the US, and it’s why we’ve made the decision to welcome them to Hims & Hers after closing. Their dedication to consumers has resulted in an incredible business with an ARR north of $450 million USD that delivered triple-digit year-over-year ARR growth every quarter last year. Together, we’re going to push the industry to put people at the center of healthcare and help more people experience care that feels like a luxury without costing like one. I have always known the value of what we’re building for customers at Hims & Hers isn’t restricted to borders. That’s even more true today. Read more here, including important footnotes and disclaimers: investors.hims.com/news/news-deta…

Tonight, when our ad airs during the Big Game, we will continue a much-needed conversation around what healthcare should look and feel like in America: affordable, proactive, personalized. When we start hard conversations, we expect challenges along the way. But we won't ever stop advocating for better until the system becomes better for everyone. news.hims.com/newsroom/the-h…

Today, we’re taking another step in making it easy to get proactive about your health. Introducing the Hims & Hers Multi-Cancer Test by Galleri®. By combining innovation from @GrailBio and the ease of our platform, we’re giving you a way to screen for a signal for 50+ types of cancer in a single blood test. Our Chief Medical Officer, Dr. Pat Carroll, has spent decades as a family physician and has seen the difference earlier access to powerful technology can make for people everywhere. Hear more from him on why we’re so committed to expanding access to proactive care. news.hims.com/newsroom/do-mo…